Stretching a doublet into a triplet for FLT3 AML

Keith W. Pratz · 2026

Read Stretching a doublet into a triplet for FLT3 AML by Keith W. Pratz (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13543938.txt.

Description

Some leukemias wired with FLT3 mutations resist standard gentle therapy, and Keith Pratz comments on a study that adds a third drug to the fight. The standard doublet pairs azacitidine with venetoclax. The commented trial adds gilteritinib, a targeted FLT3 blocker, making a triplet. Response rates reported in the underlying study were remarkably high for this hard subtype.

Pratz urges both excitement and patience. The triplet suppresses bone marrow more heavily, a serious cost for frail patients. A randomized trial now enrolling will test the triplet against the doublet directly. Until it reports, routine use should wait. The commentary captures a familiar oncology moment: a promising combination, a plausible price, and a verdict that only randomization can deliver.

Catalog record

CREATORKeith W. Pratz
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE7 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13543938

Browse the full library · About the Tower of Babel